This suggested that CHD1 loss might activate transcriptional programs that relieve prostate tumor cells from their dependence on AR by reprogramming away from their luminal lineage, as we have reported previously in the setting of combined loss of RB1 and TP53 (Ku et al., 2017, Mu et al., 2017). This evidence concerns the gene TP53 and prostate neoplasm.